{"id":455542,"date":"2025-12-23T00:00:00","date_gmt":"2025-12-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0004-2024-biopharma-atrial-fibrillation-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:23:42","modified_gmt":"2026-03-31T10:23:42","slug":"dlsfcv0004-2026-biopharma-atrial-fibrillation-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0004-2026-biopharma-atrial-fibrillation-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Atrial Fibrillation &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Atrial fibrillation (<abbr title=\"atrial fibrillation\">AF<\/abbr>) is an abnormal heart rhythm characterized by rapid and irregular beats of the atrial chambers of the heart. <abbr title=\"atrial fibrillation\">AF<\/abbr> can lead to blood clots, increasing the risk of stroke fivefold. Pharmacological treatment includes rate control therapies (e.g., beta blockers, calcium channel blockers, digoxin), rhythm control therapies (class Ic and class III antiarrhythmics), and stroke prevention agents (e.g., vitamin K antagonists, direct-acting oral anticoagulants [<abbr title=\"direct-acting oral anticoagulant\">DOAC<\/abbr>s]). Several key <abbr title=\"atrial fibrillation\">AF<\/abbr> drugs will lose patent protection during the forecast period. Novel agents that are in clinical trials to treat <abbr title=\"atrial fibrillation\">AF<\/abbr> include Novartis\u2019s abelacimab and <abbr title=\"Bristol Myers Squibb\">BMS<\/abbr> \/ Johnson &#038; Johnson Innovative Medicine\u2019s milvexian. We expect these drugs to launch during the forecast period and fulfill some of the unmet needs that remain in <abbr title=\"atrial fibrillation\">AF<\/abbr> treatment.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the key drivers and constraints in the <abbr title=\"atrial fibrillation\">AF<\/abbr> therapy market? How will current therapies perform over the forecast period?<\/li>\n<li>What do key opinion leaders think about emerging therapies such as milvexian and abelacimab? How will emerging therapies impact existing stroke prevention therapies?<\/li>\n<li>How will the genericization of the <abbr title=\"direct-acting oral anticoagulant\">DOAC<\/abbr>s affect the market?<\/li>\n<li>What are the key unmet needs in <abbr title=\"atrial fibrillation\">AF<\/abbr> treatment, and how likely will they be met during the forecast period?<\/li>\n<\/ul>\n<p><strong>Geography: <\/strong>United States, France, Germany, Italy, Spain, the United Kingdom, and Japan<\/p>\n<p><strong>Primary research:<\/strong> 19 country-specific interviews with thought-leading cardiologists. Supported by survey data collected for this and other Clarivate research.<\/p>\n<p><strong>Epidemiology:<\/strong> Total prevalent cases of <abbr title=\"atrial fibrillation\">AF<\/abbr> by country,; paroxysmal, persistent, and permanent diagnosed prevalent cases.<\/p>\n<p><strong>F<\/strong><strong>orecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key <abbr title=\"atrial fibrillation\">AF<\/abbr> therapies through 2034, segmented by brands \/ generics as well as paroxysmal, persistent, and permanent diagnosed prevalent cases.<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and late \u2013 phase emerging therapies.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-455542","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-atrial-fibrillation","biopharma-therapy-areas-cardiovascular","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/455542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/455542\/revisions"}],"predecessor-version":[{"id":575229,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/455542\/revisions\/575229"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=455542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}